In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2receptor?
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background and purpose: The CB 2 receptor has been proposed as a novel target for the treatment of pain, and CB 2 receptor agonists defined in in vitro assays have demonstrated analgesic activity in animal models. Based on its in vivo analgesic efficacy, AM1241 has been classified as a CB 2‐selective agonist. However,in vitro characterization of AM1241 in functional assays has not been reported. Experimental approach: In this study, AM1241 was characterized across multiple in vitro assays employing heterologous recombinant receptor expression systems to assess its binding potencies at the human CB 2 and CB 1 receptors and its functional efficacies at the human CB 2 receptor. Key results: AM1241 exhibited distinct functional properties depending on the assay conditions employed, a unique profile in contrast to those of the agonist CP 55,940 and the inverse agonist SR144528. AM1241 displayed neutral antagonist activities in FLIPR and cyclase assays. However, when cyclase assays were performed using lower forskolin concentrations for stimulation, AM1241 exhibited partial agonist efficacy. In addition, it behaved as a partial agonist in ERK (or MAP) kinase assays. Conclusions and implications: The unusual phenomenon of inconsistent functional efficacies suggests that AM1241 is a protean agonist at the CB 2 receptor. We postulate that functional efficacies displayed by protean agonists in various assay systems may depend on the levels of receptor constitutive activities exhibited in the assay systems, and therefore, efficacies observed in in vitro assays may not predict in vivo activities. British Journal of Pharmacology(2006)149, 145–154. doi:10.1038/sj.bjp.0706838
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092 · cited 1×
“The CB1 receptor is predominantly located in the CNS and the peripheral CB2 receptor is abundant in the immune system (Matsuda et al., 1990; Munro et al., 1993; Shire et al., 1996; Griffin et al., 2000; Brown et al., 2002).”
BackgroundStructure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011 · cited 1×
“The CB1 receptor is predominantly located in the CNS and the peripheral CB2 receptor is abundant in the immune system (Matsuda et al., 1990; Munro et al., 1993; Shire et al., 1996; Griffin et al., 2000; Brown et al., 2002).”
BackgroundInternational Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
Cannabinoid receptors and pain
Pertwee, R. G. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00031-9 · Cited by 741
Cannabinoid physiology and pharmacology: 30 years of progress
Howlett, A. C., Breivogel, C. S., Childers, S. R., Deadwyler, S. A., Hampson, R. E., & Porrino, L. J. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.07.030 · Cited by 608 · cited 1×
“The analgesic properties of herbal and synthetic cannabinoid agonists have been well established (Pertwee, 2001; Rice, 2001; Baker et al., 2003; Croxford, 2003; Howlett et al., 2004).”
BackgroundValenzano, K. J., Tafesse, L., Lee, G., Harrison, J. E., Boulet, J. M., Gottshall, S. L., Mark, L., Pearson, M. S., Miller, W., Shan, S., et al. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.12.008 · Cited by 288 · cited 4×
“, 2004), GW405833 (Valenzano et al., 2005) and AM1241 (2-iodo-5-nitrophenyl)-[1-(1-methylpiperidin-2-ylmethyl)-1H-indol-3-yl]methanone) (Ibrahim et al.”
InfluentialElmes, S. J. R., Jhaveri, M. D., Smart, D., Kendall, D. A., & Chapman, V. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03690.x · Cited by 160
Cited by
Cannabinoid Receptors: Where They are and What They do
Mackie, K. (2008) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2008.01671.x · Cited by 638
CB2: a cannabinoid receptor with an identity crisis
Atwood, B. K., & Mackie, K. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00729.x · Cited by 619
The Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 556
Emerging strategies for exploiting cannabinoid receptor agonists as medicines
Pertwee, R. G. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00048.x · Cited by 436
“…to behave in vitro as an agonist at human CB2 receptors but as an inverse agonist at mouse and rat CB2 receptors, and Yao et al. (2006) have found that R,S-AM1241 switches from producing agonism to producing inverse agonism at human CB2 receptors in vitro when the…”
BackgroundGuindon, J., & Hohmann, A. G. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707531 · Cited by 423
Brain cannabinoid CB2 receptors modulate cocaine's actions in mice
Xi, Z.-X., Peng, X.-Q., Li, X., Song, R., Zhang, H.-Y., Liu, Q.-R., Yang, H.-J., Bi, G.-H., Li, J., & Gardner, E. L. (2011) · Nature Neuroscience · doi:10.1038/nn.2874 · Cited by 397
Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity
Soethoudt, M., Grether, U., Fingerle, J., Grim, T. W., Fezza, F., de Petrocellis, L., Ullmer, C., Rothenhäusler, B., Perret, C., van Gils, N., et al. (2017) · Nature Communications · doi:10.1038/ncomms13958 · Cited by 349
CB2 Cannabinoid Receptors as a Therapeutic Target—What Does the Future Hold?
Dhopeshwarkar, A., & Mackie, K. (2014) · Molecular Pharmacology · doi:10.1124/mol.114.094649 · Cited by 257
Janero, D. R., & Makriyannis, A. (2009) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210902736568 · Cited by 186
“, variable GPCR:G protein ratios), it is imperative to conduct direct comparisons among several receptor ligands in a given cell system to ensure reliable pharmacological GPCR ligand characterization [102,103] .”
BackgroundInfluentialYao, B. B., Hsieh, G. C., Frost, J. M., Fan, Y., Garrison, T. R., Daza, A. V., Grayson, G. K., Zhu, C. Z., Pai, M., Chandran, P., et al. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707568 · Cited by 140
Self-citationRahn, E. J., Zvonok, A. M., Thakur, G. A., Khanolkar, A. D., Makriyannis, A., & Hohmann, A. G. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.141994 · Cited by 116
Yao, B. B., Hsieh, G., Daza, A. V., Fan, Y., Grayson, G. K., Garrison, T. R., El Kouhen, O., Hooker, B. A., Pai, M., Wensink, E. J., et al. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.145011 · Cited by 92
Self-citationYamamoto, W., Mikami, T., & Iwamura, H. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.01.010 · Cited by 89
Sain, N. M. H., Liang, A., Kane, S. A., & Urban, M. O. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.06.004 · Cited by 51
Metadata
- Authors
- Yao, B. B., Mukherjee, S., Fan, Y., Garrison, T. R., Daza, A. V., Grayson, G. K., Hooker, B. A., Dart, M. J., Sullivan, J. P., & Meyer, M. D.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2006-09
- Volume
- 149
- Issue
- 2
- Pages
- 145-154
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1495173924
- Cited by
- 116
- References
- 7
- FWCI
- 5.66
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.